DDInter1346 DDInter1676
A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Orciprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Orciprenaline {u} (Compound) resembles {v} (Compound) Fenoterol
Orciprenaline {u} (Compound) resembles {v} (Compound) Terbutaline
Orciprenaline {u} (Compound) treats {v} (Disease) asthma
Orciprenaline {u} (Compound) binds {v} (Gene) ADRB2
Orciprenaline {u} (Compound) upregulates {v} (Gene) DDX10
Orciprenaline {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Orciprenaline {u} (Compound) downregulates {v} (Gene) SLC2A6
Orciprenaline {u} (Compound) causes {v} (Side Effect) Dizziness
Orciprenaline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Betamethasone
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine
Orciprenaline (Compound) resembles Fenoterol (Compound)
Orciprenaline (Compound) resembles Terbutaline (Compound)
Orciprenaline (Compound) treats asthma (Disease)
Orciprenaline (Compound) binds ADRB2 (Gene)
Orciprenaline (Compound) upregulates DDX10 (Gene)
Orciprenaline (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Orciprenaline (Compound) downregulates SLC2A6 (Gene)
Orciprenaline (Compound) causes Dizziness (Side Effect)
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Betamethasone